PubMatic Inc vs Roivant Sciences Ltd. Common Shares — how do they compare? PubMatic Inc trades at $18.56 (market cap $845.86M), while Roivant Sciences Ltd. Common Shares trades at $34.21 (market cap $25.09B). The key difference: Roivant Sciences Ltd. Common Shares is far larger — about 29.7× PubMatic Inc's market cap, and PubMatic Inc is trading nearer its 52-week high, Roivant Sciences Ltd. Common Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold PubMatic Inc for 40 Days and Roivant Sciences Ltd. Common Shares for 0 Days on average.
| PUBM | ROIV | |
|---|---|---|
Market Cap | $845.86M | $25.09B |
Volume | 519,667 | 5,738,571 |
Sector | Technology | Health |
52-Week High | $19.18 | $41.81 |
52-Week Low | $6.28 | $16.04 |
Typical Hold Time | 40 Days | 0 Days |
Enterprise Value | $748.99M | $21.36B |
Signals from Pluang's Aura AI — not financial advice
PubMatic (PUBM) trades at $18.68, up 1.8% with bullish technical signals and strong analyst support. The stock shows positive momentum with recent earnings beats and double-digit revenue growth in Q2 2026. Despite negative net margins, the company maintains robust gross margins of 64.43% and positive operating cash flow of $81.06M in 2025. Recent leadership appointments and AI product launches signal strategic growth initiatives.
The outlook remains cautiously optimistic with Wall Street consensus at Buy (64.7%) and $19.89 price target. Key risks include persistent profitability challenges and competitive pressures in digital advertising. The stock's elevated P/E of 132 reflects growth expectations but requires sustained execution to justify valuation.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
PubMatic Inc is engaged in the digital advertising business. The company provides a specialized cloud infrastructure platform that enables real-time programmatic advertising transactions. The platform helps independent app developers and publishers to control and maximize their digital advertising businesses.
Read more on PUBM →Roivant Sciences develops medicines by building and supporting biotechnology subsidiaries, known as Vants. Its programs span areas such as immunology, neuroscience, and rare diseases.
Read more on ROIV →